Conformis (NASDAQ:CFMS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Conformis (NASDAQ:CFMS – Get Rating) in a research note issued to investors on Saturday. The brokerage issued a hold rating on the medical instruments supplier’s stock.

Separately, Zacks Investment Research raised Conformis from a strong sell rating to a hold rating in a research note on Wednesday, May 4th.

CFMS opened at $0.42 on Friday. The firm has a market cap of $77.51 million, a P/E ratio of -10.45 and a beta of 1.42. Conformis has a 52-week low of $0.29 and a 52-week high of $1.96. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.87 and a current ratio of 6.84. The business’s fifty day moving average is $0.56 and its 200-day moving average is $0.68.

Conformis (NASDAQ:CFMS – Get Rating) last released its earnings results on Wednesday, May 4th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Conformis had a negative return on equity of 6.50% and a negative net margin of 6.83%. During the same period last year, the business earned ($0.09) EPS. On average, research analysts predict that Conformis will post -0.31 earnings per share for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada acquired a new stake in Conformis in the third quarter valued at about $39,000. Morgan Stanley raised its position in Conformis by 657.6% in the first quarter. Morgan Stanley now owns 29,283 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 25,418 shares during the last quarter. Citadel Advisors LLC bought a new position in Conformis in the third quarter valued at about $52,000. Lake Street Financial LLC bought a new position in Conformis in the fourth quarter valued at about $31,000. Finally, Virtu Financial LLC bought a new position in Conformis in the first quarter valued at about $40,000. 51.01% of the stock is currently owned by institutional investors and hedge funds.

About Conformis (Get Rating)

Conformis, Inc, a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products.

Recommended Stories